- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
MERCK / SANOFI PASTEUR MSD
M.8083
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
This Transaction concerns the termination of Sanofi Pasteur MSD SNC (“SPMSD”) as a joint venture between Merck & Co., Inc. (“Merck”, known as Merck Sharp & Dohme or MSD outside the United States and Canada) and Sanofi Pasteur SA (“SP”), active in the commercialization of vaccines in certain European countries. Following SP’s repurchase of its own assets from SPMSD, Merck will acquire sole control of the SPMSD entity, which will survive as a wholly owned subsidiary of Merck and consist solely of the assets contributed by Merck.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.